Anti CD-30 Antibody-Drug Conjugate Brentuximab Vedotin (ADCETRIS®) May Be a Promising Treatment Option for Systemic Mastocytosis (SM).

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Blood

• Publication date

  2012-11-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V120.21.2857.2857
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Immune checkpoint-targeted drug conjugates: A promising tool for remodeling tumor immune microenvironment.

  2023cites this paper
• Aggressive Systemic Mastocytosis in Association with Pure Red Cell Aplasia

  2018cites this paper
• Bioproduction of Antibody-Drug Conjugate Payload Precursors by Engineered Cell Factories.

  2017cites this paper
• Shared clonal cytogenetic abnormalities in aberrant mast cells and leukemic myeloid blasts detected by single nucleotide polymorphism microarray‐based whole‐genome scanning

  2016cites this paper
• Brentuximab Vedotin (Adcetris®) for the Treatment of CD30‐Positive Hematologic Malignancies

  2014cites this paper
• Monoclonal antibody therapy for classical Hodgkin lymphoma

  2013cites this paper
• Brentuximab Vedotin: A CD30‐Directed Antibody‐Cytotoxic Drug Conjugate

  2013cites this paper
• CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis

  2013cites this paper